EUVIMEDEUVIMED entdecken
LeserbriefOpen Access · CC BY-NC-ND 4.0

Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan

J David Smeijer iD, Donald E Kohan iD, Dick de Zeeuw, Hiddo J L Heerspink iD

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15110 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von J David Smeijer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Heart Failure, Diabetic Nephropathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endothelin-1 is an endogenous peptide that has been implicated in the progression of chronic kidney disease (CKD). 1 ET A receptor inhibition with atrasentan reduced the risk of major clinical kidney outcomes in patients with type 2 diabetes and CKD in the SONAR trial. 2 However, ET A receptor antagonists (ERAs), including atrasentan, can cause sodium and fluid retention, leading to oedema and possibly heart failure. 3,4The nephron site(s) responsible for ERA-induced fluid

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureDiabetic NephropathiesHumansAtrasentanEndothelin Receptor AntagonistsDiureticsEndothelin A Receptor AntagonistsPyrrolidinesBiomarkers

Stichwörter der Autor:innen

clinical trialdiabetic nephropathyendothelin receptor antagonistheart failure

Substanzen

AtrasentanEndothelin Receptor AntagonistsDiureticsEndothelin A Receptor AntagonistsPyrrolidinesBiomarkers

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.
  • Division of Nephrology, University of Utah Health, Salt Lake City, Utah, USA.

ORCID-Profile: J David Smeijer, Donald E Kohan, Hiddo J L Heerspink

Förderung

  • Innovative Medicines Initiative

Zitieren

APA

Smeijer, J. D., Kohan, D. E., de Zeeuw, D., & Heerspink, H. J. L. (2023). Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15110

Vancouver

Smeijer JD, Kohan DE, de Zeeuw D, Heerspink HJL. Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15110

BibTeX
@article{Smeijer2023,
  author = {Smeijer, J David and Kohan, Donald E and de Zeeuw, Dick and Heerspink, Hiddo J L},
  title = {Diuretic medication and change in fluid retention biomarkers during treatment with the endothelin receptor antagonist atrasentan},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15110}
}
Kostenlos starten →